InhalPlus Receives €2.8 Million in Non-Dilutive Funding

🚀 This Wednesday we received both official grant notifications—now it’s 100% confirmed: €2.8M in non-dilutive funding is secured! 👀

We’re incredibly proud and grateful to announce that we have successfully secured separate grants from exist – from science to business (€1.5M, starting December 2024) and from the Institute for Biomedical Translation (IBT Lower Saxony) (€1.3M, starting April 2025). Each grant supports a distinct phase of our journey, ensuring no overlap in funding.

EXIST:
With support from EXIST, we’ll refine our current prototype at Fraunhofer ITEM and work closely with nursing staff and neonatologists to enhance usability. During this period, we’ll also address critical regulatory steps—preparing comprehensive documentation and processes for the required CE clinical study, which is essential for market entry.

IBT:
Through the IBT Lower Saxony grant, our clinical partners at Hannover Medical School and University Hospital Schleswig-Holstein will conduct a clinical proof-of-concept study. This will validate our efficiency advantage in real-world conditions.

This funding isn’t just financial support—it’s a strong vote of confidence in our vision to improve neonatal care. Stay tuned as we move forward, building evidence, refining our technology and striving to make a lasting difference for preterm infants worldwide!